[go: up one dir, main page]

HUP0004426A2 - RAF kináz gátló hatású, aril- és heteroarilcsoporttal szubsztituált heterociklusos karbamidszármazékok és ezeket tartalmazó gyógyászati készítmények - Google Patents

RAF kináz gátló hatású, aril- és heteroarilcsoporttal szubsztituált heterociklusos karbamidszármazékok és ezeket tartalmazó gyógyászati készítmények

Info

Publication number
HUP0004426A2
HUP0004426A2 HU0004426A HUP0004426A HUP0004426A2 HU P0004426 A2 HUP0004426 A2 HU P0004426A2 HU 0004426 A HU0004426 A HU 0004426A HU P0004426 A HUP0004426 A HU P0004426A HU P0004426 A2 HUP0004426 A2 HU P0004426A2
Authority
HU
Hungary
Prior art keywords
group
aryl
nr5c
heteroaryl
nr5r5
Prior art date
Application number
HU0004426A
Other languages
English (en)
Inventor
Jacques Dumas
Holia Hatoum-Mokdad
Jeffrey Johnson
Uday Khire
Timothy Bruno Lowinger
Holger Paulsen
Aniko Redman
Bernd Riedl
William J. Scott
Robert Sibley
Roger A. Smith
Jill E. Wood
Original Assignee
Bayer Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corporation filed Critical Bayer Corporation
Publication of HUP0004426A2 publication Critical patent/HUP0004426A2/hu
Publication of HUP0004426A3 publication Critical patent/HUP0004426A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

A találmány tárgyát (I) általános képletű vegyületek ésezek gyógyá- szatilag megfelelő sói, valamint ezeket tartalmazógyógyászati készítmények képezik. A vegyületek előnyösen adhatók RAFkináz által közvetített betegségek kezelésére, ezen betegségek közülemlítjük meg a rák különböző alakjait, tüdőkarcinómát, hasnyálmirigyrákot, vastagbél rákot és hasonlókat. Az (I) általános képletben aszubsztituensek jelentése igen sokféle, így például A jelentése (A-a),(A-b) vagy (A-c) általános képletű heteroarilcsoport, ahol aképletekben R1 jelentése például alkil-, cikloalkilcsoport, halogénnelszubsztituálható alkilcsoport, B jelentése például aril- vagyheteroarilcsoport, amely legalább egy 5- vagy 6-tagú aromás gyűrűttartalmaz, amelyben 0-4 gyűrűtag nitrogénatomot, oxigénatomot és/vagykénatomot képez, és ahol a B helyében álló csoport - amennyibenszubsztituenst hordoz, úgy az egymástól függetlenül egy vagy többhalogénnel a perhalogén szubsztituáltságig vagy Xn csoporttal lehetszubsztituálva; ahol n értéke 0, 1, 2 vagy 3, és mindegyik X jelentéseegymástól függetlenül például -CN, -CO2R5, -C(O)NR5R5,, -C(O)R5,, -NO2, -OR5, -SR5, -NR5R5,, -NR5C(O)OR5,, -NR5C(O)R5,, alkil-, alkenil-,alkoxi-, cikloalkil-, aril-, aralkil-, heteroaril-, alkil-heteroarilcsoport; amennyiben X jelentése szubsztituált csoport, úgyszubsztituensként egy vagy több -CN, -CO2R5, -C(O)R5, -C(O)NR5R5,, -OR5, -SR5, -NR5R5,, -NO2, -NR5C(O)R5,, -NR5C(O)OR5, vagy halogénatom aperhalogén szubsztituáltságig csoportot hordozhat; ahol az R5 és R5'csoportok jelentése például alkil-, alkenil-, cikloalkil-, aril-,heteroaril-, aralkil-, alkil-heteroarilcsoport, Y jelentése -O-, -S-,-N(R5)-, -(CH2)m-, -C(O)-, -CH(OH)-, -(CH2)mO-, -NR5C(O)NR5R5,, -NR5C(O)-, -C(O)NR5-, -O(CH2)m-, -(CH2)mS-, -(CH2)mN(R5)-, -O(CH2)m-, -CHXa, -CXa2-, -S-(CH2)m- vagy -N(R5)(CH2)m-, m értéke 1-3 és Xajelentése halogénatom, és Ar jelentése előnyösen 5-10 tagból állóaromás szerkezet, R2 jelentése aril-, heteroarilcsoport, szubsztituáltaril- vagy szubsztituált heteroarilcsoport, R5 és R5, jelentéseelőnyösen egymástól függetlenül a fentiekben megadottal azonos. Ó
HU0004426A 1997-12-22 1998-12-22 Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas HUP0004426A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99618197A 1997-12-22 1997-12-22
PCT/US1998/026082 WO1999032455A1 (en) 1997-12-22 1998-12-22 Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas

Publications (2)

Publication Number Publication Date
HUP0004426A2 true HUP0004426A2 (hu) 2001-05-28
HUP0004426A3 HUP0004426A3 (en) 2001-07-30

Family

ID=25542594

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0004426A HUP0004426A3 (en) 1997-12-22 1998-12-22 Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas

Country Status (29)

Country Link
EP (1) EP1056725B1 (hu)
JP (1) JP4395823B2 (hu)
KR (1) KR100622138B1 (hu)
CN (1) CN1117081C (hu)
AT (1) ATE328873T1 (hu)
AU (1) AU765412B2 (hu)
BG (1) BG65207B1 (hu)
BR (1) BR9814361A (hu)
CA (1) CA2315713C (hu)
CU (1) CU23127A3 (hu)
CY (1) CY1105395T1 (hu)
CZ (1) CZ299836B6 (hu)
DE (2) DE69834842T2 (hu)
DK (1) DK1056725T3 (hu)
ES (1) ES2155045T3 (hu)
GR (1) GR20010300010T1 (hu)
HK (1) HK1029989A1 (hu)
HU (1) HUP0004426A3 (hu)
ID (1) ID26328A (hu)
IL (2) IL136773A0 (hu)
NO (1) NO319209B1 (hu)
NZ (1) NZ505845A (hu)
PL (1) PL341356A1 (hu)
PT (1) PT1056725E (hu)
RU (1) RU2265597C2 (hu)
SK (1) SK285371B6 (hu)
TR (3) TR200100917T2 (hu)
UA (1) UA67763C2 (hu)
WO (1) WO1999032455A1 (hu)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1473292A1 (en) * 1997-11-03 2004-11-03 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
AU2006201959B2 (en) * 1997-12-22 2008-09-04 Bayer Healthcare Llc Inhibition of Raf Kinase using Substituted Heterocyclic Ureas
MXPA00006233A (es) * 1997-12-22 2002-09-18 Bayer Ag Inhibicion de la actividad de la cinasa p38 utilizando ureas heterociclicas sustituidas.
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
CA2315717C (en) * 1997-12-22 2011-02-01 Bayer Corporation Inhibition of raf kinase using substituted heterocyclic ureas
IL136768A0 (en) * 1997-12-22 2001-06-14 Bayer Ag INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7928239B2 (en) * 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
CA2359244C (en) 1999-01-13 2013-10-08 Bayer Corporation .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
WO2000050425A1 (en) 1999-02-22 2000-08-31 Boehringer Ingelheim Pharmaceuticals, Inc. Polycyclo heterocyclic derivatives as antiinflammatory agents
EP1159273A1 (en) 1999-03-02 2001-12-05 Boehringer Ingelheim Pharmaceuticals Inc. Compounds useful as reversible inhibitors of cathepsin s
ATE309237T1 (de) 1999-03-12 2005-11-15 Boehringer Ingelheim Pharma Aromatische heterozyklische verbindungen als antientzündungwirkstoffe
NZ528846A (en) 1999-03-12 2005-05-27 Boehringer Ingelheim Pharma Compounds useful as anti-inflammatory agents
WO2001004115A2 (en) 1999-07-09 2001-01-18 Boehringer Ingelheim Pharmaceuticals, Inc. Novel process for synthesis of heteroaryl-substituted urea compounds
AU4971400A (en) * 1999-08-12 2001-03-13 Pharmacia & Upjohn Company 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
KR20020050294A (ko) * 1999-11-22 2002-06-26 피터 기딩스 신규화합물
US6525046B1 (en) 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
US6608052B2 (en) 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
DE60143041D1 (de) 2000-08-10 2010-10-21 Pfizer Italia Srl Bizyklische pyrazole wirksam als kinase inhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
US6645990B2 (en) 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
US7238813B2 (en) 2000-11-29 2007-07-03 Smithkline Beecham Corporation Chemical compounds
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
WO2002092576A1 (en) 2001-05-16 2002-11-21 Boehringer Ingelheim Pharmaceuticals, Inc. Diarylurea derivatives useful as anti-inflammatory agents
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
CA2448626A1 (en) 2001-05-25 2002-12-05 Boehringer Ingelheim Pharmaceuticals, Inc. Carbamate and oxamide compounds as inhibitors of cytokine production
EP1709965A3 (en) * 2001-07-11 2006-12-27 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediate diseases
US7375105B2 (en) 2001-09-05 2008-05-20 Smithkline Beecham P.L.C. Pyridine substituted furan derivatives as Raf kinase inhibitors
SI2305255T1 (sl) * 2001-12-03 2012-10-30 Bayer Healthcare Llc Arilsečninske spojine v kombinaciji z drugimi citostatičnimi ali citotoksičnimi sredstvi za zdravljenje človeških rakov
US10653684B2 (en) 2002-02-11 2020-05-19 Bayer Healthcare Llc Aryl ureas with angiogenisis inhibiting activity
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
PT1580188E (pt) 2002-02-11 2012-01-25 Bayer Healthcare Llc Aril-ureias como inibidores de cinases
AU2003210969A1 (en) * 2002-02-11 2003-09-04 Bayer Corporation Aryl ureas with raf kinase and angiogenesis inhibiting activity
WO2003072569A1 (en) 2002-02-25 2003-09-04 Boehringer Ingelheim Pharmaceuticals, Inc. 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
US20060135508A1 (en) * 2002-07-25 2006-06-22 Manuela Villa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
JP5229853B2 (ja) 2003-02-28 2013-07-03 ニッポネックス インコーポレイテッド 癌その他の疾患の治療に有用な新規な二環尿素誘導体
EP1633758B1 (en) 2003-05-15 2011-11-23 Arqule, Inc. Imidazothiazoles and imidazoxazole derivatives as inhibitors of p38
WO2004113274A2 (en) 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
RS52625B (en) 2003-07-23 2013-06-28 Bayer Healthcare Llc FLUORO SUBSTITUTED OMEGA-CARBOXYARYL DIPHENYL UREA FOR TREATMENT AND PREVENTION OF DISEASES AND DISEASES
EP1684762A4 (en) * 2003-11-13 2009-06-17 Ambit Biosciences Corp UREA DERIVATIVES AS MODULATORS OF KINASE
TW200530236A (en) 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
ATE496036T1 (de) * 2004-03-19 2011-02-15 Dipharma Francis Srl Zwischenprodukte für die herstellung von pramipexol
CA2564325A1 (en) 2004-04-30 2005-11-24 Bayer Pharmaceuticals Corporation Substituted pyrazolyl urea derivatives useful in the treatment of cancer
US7829560B2 (en) 2004-07-08 2010-11-09 Arqule, Inc. 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
CA2584368A1 (en) 2004-10-19 2006-04-27 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
GB0423554D0 (en) * 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
CA2592118C (en) 2004-12-23 2015-11-17 Deciphera Pharmaceuticals, Llc Urea derivatives as enzyme modulators
GB0500435D0 (en) * 2005-01-10 2005-02-16 Novartis Ag Organic compounds
BRPI0608840B8 (pt) 2005-03-07 2021-05-25 Batyer Healthcare Ag composição farmacêutica compreendendo uma difenil uréia substituída por ômega-carboxiarila, e seu processo de preparação
US8299252B2 (en) 2005-08-05 2012-10-30 Chugai Seiyaku Kabushiki Kaisha Pyrazolopyridine and pyrrolopyridine multikinase inhibitors
DE102005037499A1 (de) * 2005-08-09 2007-02-15 Merck Patent Gmbh Pyrazolderivate
EP1960394A2 (en) * 2005-11-15 2008-08-27 Bayer HealthCare AG Pyrazolyl urea derivatives useful in the treatment of cancer
WO2007075650A2 (en) * 2005-12-21 2007-07-05 Bayer Healthcare Ag Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders
JP2009538317A (ja) 2006-05-26 2009-11-05 バイエル ヘルスケア リミティド ライアビリティ カンパニー 癌治療のための置換ジアリールウレアを用いた薬物の組み合わせ
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
EP2134677B1 (en) 2006-12-20 2011-10-12 Bayer HealthCare LLC 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl)phenyl]-1h-pyrazol-5-yl}carbamoyl)-amino]-3-chlorophenoxy}-n-methylpyridine-2-carboxamide as an inhibitor of the vegfr kinase for the treatment of cancer
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
EP2136639B1 (en) 2007-04-02 2016-03-09 Evotec AG Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof
KR20100017184A (ko) 2007-04-20 2010-02-16 데시페라 파마슈티칼스, 엘엘씨. 골수증식성 질환 및 다른 증식성 질환의 치료에 유용한 키나제 억제제
MX2010009410A (es) 2008-02-29 2010-11-30 Array Biopharma Inc Compuestos del inhibidor de raf y métodos de uso de los mismos.
US8394795B2 (en) 2008-02-29 2013-03-12 Array Biopharma Inc. Pyrazole [3, 4-B] pyridine Raf inhibitors
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
KR20110070887A (ko) 2008-10-02 2011-06-24 레스피버트 리미티드 Ｐ38 엠에이피 키나제 억제제
JP5670912B2 (ja) 2008-12-11 2015-02-18 レスピバート・リミテツド ｐ３８ＭＡＰキナーゼ阻害剤
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
US9260410B2 (en) 2010-04-08 2016-02-16 Respivert Ltd. P38 MAP kinase inhibitors
WO2012008563A1 (ja) 2010-07-16 2012-01-19 協和発酵キリン株式会社 含窒素芳香族複素環誘導体
WO2012012404A1 (en) 2010-07-19 2012-01-26 Bayer Healthcare Llc Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
EA023650B1 (ru) 2011-10-03 2016-06-30 Респайверт Лимитед 1-ПИРАЗОЛИЛ-3-(4-((2-АНИЛИНОПИРИМИДИН-4-ИЛ)ОКСИ)НАФТАЛИН-1-ИЛ)МОЧЕВИНЫ КАК ИНГИБИТОРЫ p38 MAP-КИНАЗЫ
EP2578582A1 (en) 2011-10-03 2013-04-10 Respivert Limited 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
KR20140011780A (ko) * 2012-07-19 2014-01-29 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 이소퀴놀린-5-카복스아미드 유도체
GB201214750D0 (en) 2012-08-17 2012-10-03 Respivert Ltd Compounds
GB201215357D0 (en) 2012-08-29 2012-10-10 Respivert Ltd Compounds
US20160016934A1 (en) 2013-03-14 2016-01-21 Respivert Limited Kinase inhibitors
WO2015066490A1 (en) 2013-10-31 2015-05-07 Ohio University Prevention and treatment of non-alcoholic fatty liver disease
PT3105222T (pt) 2014-02-14 2018-07-18 Respivert Ltd Compostos heterocíclicos aromáticos como compostos anti-inflamatórios
WO2016010609A1 (en) 2014-07-18 2016-01-21 Ohio University Prevention and treatment of non-alcoholic fatty liver disease
CN111886006B (zh) 2018-01-31 2024-07-09 德西费拉制药有限责任公司 治疗肥大细胞增多症的组合疗法
EP3746059A1 (en) 2018-01-31 2020-12-09 Deciphera Pharmaceuticals, LLC Combination therapy for the treatment of gastrointestinal stromal tumors
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
CN108484587A (zh) * 2018-06-03 2018-09-04 刘思良 一种Raf激酶抑制剂及其在癌症治疗中的应用
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
WO2020010155A1 (en) * 2018-07-03 2020-01-09 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
CA3150433A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
HRP20231699T1 (hr) 2019-12-30 2024-05-10 Deciphera Pharmaceuticals, Llc Formulacije inhibitora amorfne kinaze i postupci njihove primjene
JP7534416B2 (ja) 2019-12-30 2024-08-14 デシフェラ・ファーマシューティカルズ，エルエルシー １－（４－ブロモ－５－（１－エチル－７－（メチルアミノ）－２－オキソ－１，２－ジヒドロ－１，６－ナフチリジン－３－イル）－２－フルオロフェニル）－３－フェニル尿素の組成物
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162360A (en) * 1991-06-24 1992-11-10 Warner-Lambert Company 2-heteroatom containing urea and thiourea ACAT inhibitors
GB9302275D0 (en) * 1993-02-05 1993-03-24 Smithkline Beecham Plc Novel compounds
US5773459A (en) * 1995-06-07 1998-06-30 Sugen, Inc. Urea- and thiourea-type compounds
GB9623833D0 (en) * 1996-11-16 1997-01-08 Zeneca Ltd Chemical compound
JP2002500650A (ja) * 1997-05-23 2002-01-08 バイエル、コーポレイション Ｒａｆキナーゼ阻害剤
EP1028953A1 (en) * 1997-11-03 2000-08-23 Boehringer Ingelheim Pharmaceuticals Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
IL136768A0 (en) * 1997-12-22 2001-06-14 Bayer Ag INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS

Also Published As

Publication number Publication date
SK9622000A3 (en) 2001-01-18
NO20003231D0 (no) 2000-06-21
PL341356A1 (en) 2001-04-09
AU765412B2 (en) 2003-09-18
DK1056725T3 (da) 2006-10-02
WO1999032455A1 (en) 1999-07-01
HUP0004426A3 (en) 2001-07-30
CN1283192A (zh) 2001-02-07
ES2155045T1 (es) 2001-05-01
JP4395823B2 (ja) 2010-01-13
DE69834842D1 (de) 2006-07-20
CZ20002349A3 (en) 2001-05-16
AU1905599A (en) 1999-07-12
EP1056725A4 (en) 2001-02-07
CU23127A3 (es) 2006-04-18
CY1105395T1 (el) 2010-07-28
NZ505845A (en) 2003-10-31
ID26328A (id) 2000-12-14
DE69834842T2 (de) 2007-05-10
EP1056725B1 (en) 2006-06-07
IL136773A0 (en) 2001-06-14
DE1056725T1 (de) 2001-06-07
KR20010033513A (ko) 2001-04-25
EP1056725A1 (en) 2000-12-06
BR9814361A (pt) 2001-11-27
CN1117081C (zh) 2003-08-06
BG65207B1 (bg) 2007-07-31
BG104598A (en) 2001-02-28
KR100622138B1 (ko) 2006-09-13
NO319209B1 (no) 2005-06-27
NO20003231L (no) 2000-08-22
CA2315713A1 (en) 1999-07-01
PT1056725E (pt) 2006-09-29
TR200002617T2 (tr) 2000-11-21
GR20010300010T1 (en) 2001-03-30
CZ299836B6 (cs) 2008-12-10
UA67763C2 (uk) 2004-07-15
TR200100917T2 (tr) 2001-07-23
SK285371B6 (sk) 2006-12-07
ES2155045T3 (es) 2007-02-01
ATE328873T1 (de) 2006-06-15
JP2001526269A (ja) 2001-12-18
TR200100918T2 (tr) 2001-06-21
HK1029989A1 (en) 2001-04-20
RU2265597C2 (ru) 2005-12-10
CA2315713C (en) 2011-02-01
IL136773A (en) 2006-10-31

Similar Documents

Publication Publication Date Title
HUP0004426A2 (hu) RAF kináz gátló hatású, aril- és heteroarilcsoporttal szubsztituált heterociklusos karbamidszármazékok és ezeket tartalmazó gyógyászati készítmények
ES2155817T1 (es) Inhibicion de la actividad de la quinasa p38 utilizando ureas heterociclicas sustituidas con arilo y heteroarilo.
HUP0004437A2 (hu) Raf kinázt gátló hatású, szimmetrikusan és aszimmetrikusan szubsztituált difenil-karbamid-származékok és ezeket a vegyületeket tartalmazó gyógyászati készítmények
RU2005140570A (ru) Фармацевтическая композиция, содержащая ингибитор гистондеацетилазы
DE3881472D1 (de) Heterocyclische verbindungen mit therapeutischer wirkung.
HUP0102295A2 (hu) Citokinek által közvetített betegségek kezelésére alkalmas benzamid-származékok
HUP9900006A2 (hu) Ciklikus GMP-specifikus foszfo-diészteráz inhibitor vegyületek, előállításuk és ezeket tartalmazó gyógyszerkészítmények
HUP0102793A2 (hu) Agydaganat kezelésére szolgáló kinazolinok és ezeket tartalmazó gyógyszerkészítmények
HUP0300382A2 (hu) 2-Szubsztituált-4-heteroaril-pirimidinek és alkalmazásuk proliferatív rendellenességek kezelésében és a vegyületeket tartalmazó gyógyszerkészítmények
HUP9700126A2 (hu) 2-Oxo- és 2-tio-1,2-dihidrokinolinil-oxazolidinon-származékok és ezeket tartalmazó gyógyszerkészítmények, eljárás előállításukra és intermedierjeik
FI950375A0 (fi) c-AMP-fosfodiesteraasin ja TFN:n estäjät
HUP0300866A2 (hu) Omega-karboxi-arilcsoporttal helyettesített difenil-karbamidok, mint raf-kináz inhibitorok és ezeket tartalmazó gyógyszerkészítmények
HUP0003250A1 (hu) Káliumcsatorna gátló hatású indánszármazékok és az ezeket tartalmazó gyógyszerkészítmények
HUP0104497A2 (hu) Benzamidszármazékok, előállításuk, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0301404A2 (hu) Azetidinszármazékok, előállításuk és ezeket tartalmazó gyógyszerkészítmények és eljárás a vegyületek előállítására
HUP0302969A2 (hu) NPY Y5 antagonisták, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
NO914960D0 (no) Medikamenter for canserterapi med antihistaminegenskaper
HUP9900607A2 (hu) Pirido[2,3-d]-pirimidin-származékok és a vegyületeket tartalmazó gyógyászati készítmények
ATE161723T1 (de) Arzneimittel zur verwendung bei der behandlung von parkinsonismus
ATE34976T1 (de) Arylcyclobutylalkylamine und ihre verwendung als antidepressive arzneimittel.
HUP0003068A2 (hu) Sejtburjánzást gátló kalkonszármazékok, ezeket tartalmazó gyógyászati készítmények, alkalmazásuk gyógyszerként, valamint gyógyászati készítmények előállítására
HUP9901389A2 (hu) Központi idegrendszerre ható piperidin- és pirrolidinszármazékok, a vegyületeket tartalmazó gyógyászati készítmények, előállításuk és alkalmazásuk
HUP9802042A2 (hu) Taxoidok, előállításuk és ezeket tartalmazó gyógyszerkészítmények
DE60009868T2 (de) Anti-tumor dihydrochinazolindervate
FR2663331B1 (fr) Nouveaux derives de l'oxazole, leur preparation et les compositions pharmaceutiques qui les contiennent.

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees